For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the introduction of Tafamidis and Attruby represents a true change. These novel therapies preserve the transthyretin protein, preventing its damaging build-up and alleviating the burden of the disease .